article thumbnail

Bioavailability Enhancement Technologies

Roots Analysis

A study conducted on terminated drug development projects revealed that majority of the drug candidates fail in early drug development phases, due to the problems associated with their pharmacokinetic profiles, ADME ( distribution, metabolism, absorption and excretion ) properties and toxicity-related issues.

article thumbnail

Small matter, big challenges: Nano milling in a sterilised environment 

Pharmaceutical Technology

Nano milling is a vital technique for developing fine particle-sized drug formulations and improving bioavailability of water-soluble APIs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hot-melt extrusion can improve bioavailability: Avomeen

Outsourcing Pharma

With bioavailability challenges a frequent frustration for drug developers, one research outfit suggests a technique that could reduce the headaches.

article thumbnail

dsm-firmenich launches CBtru, revolutionizing CBD drug development with enhanced bioavailability

Outsourcing Pharma

dsm-firmenich has announced the launch of CBtru â an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats.

article thumbnail

Zerion and Insud to develop Dispersome formulations of drugs

Pharmaceutical Technology

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

article thumbnail

Enanta secures FDA fast track designation for EDP-323 to treat RSV

Pharmaceutical Technology

Furthermore, EDP-323 claims to have a favourable oral bioavailability with good plasma exposure in preclinical species and pharmacokinetic properties and supports once-a-day, oral dosage in humans. We believe this designation will be a valuable component of our clinical and regulatory strategy as we progress EDP-323 in development.”

In-Vitro 276
article thumbnail

Novaliq’s dry eye disease therapy receives US FDA approval

Pharmaceutical Technology

VEVYE, the development name of which is CyclASol, is a cyclosporine, solubilised solution in a new, water-free excipient. The water-free formulation of the investigational drug increases residual time on the surface of the eye and improves bioavailability in the target tissues to release the complete potential of cyclosporine A.